ASCO 2025 Phase 3 AMPLITUDE trial, Niraparib and abiraterone acetate plus prednisone, metastatic castration-sensitive prostate cancer, alterations in homologous recombination repair genes.

ASCO 2025 multimodal artificial intelligence (MMAI) model, androgen receptor pathway inhibitors (ARPI), high-risk non-metastatic prostate cancer, STAMPEDE.

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 and June 3 was host to the Poster Session: Genitourinary Cancer - Prostate, ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, was host to the Oral Abstract Session: Genitourinary Cancer—Prostate, Testicular, and Penile.

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, was host to the Oral Abstract Session: Genitourinary Cancer—Prostate, Testicular, and Penile.